Company / Free Cash Flow per Share
Edgewise Therapeutics, Inc. Free Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$1.40
FY2025
5-year range
-$1.53 / -$0.91
FY2021-FY2025
Trend
-17.2%
vs FY2024
Sector context
#119 of 192
Health Care
What the data says
At $-1.40, Edgewise Therapeutics, Inc.'s free cash flow per share ranks #119 of 192 in the Health Care sector. Free Cash Flow per Share has fluctuated over the past 6 years, ranging from $-20.08 in FY2020 to $-0.91 in FY2021.
Based on SEC 10-K filings.
-1.40 in FY2025.
Improved from $-1.53 to $-1.40 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#119 of 192 in Health CareTop 62% of 192This company -$1.40 Sector average $3.32
▼
-142.2% below sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 17.2% year-over-year.
- Ranks #119 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2021.
- Lowest free cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.40 | -17.2% |
| FY2024 | -$1.19 | +22.1% |
| FY2023 | -$1.53 | -41.2% |
| FY2022 | -$1.09 | -19.2% |
| FY2021 | -$0.91 | +95.5% |
| FY2020 | -$20.08 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026